Compare MiniMed Group Inc. Common Stock (MMED) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MiniMed Group Inc. Common Stock vs Rocket Companies Inc. Class A Common Stock — how do they compare? MiniMed Group Inc. Common Stock trades at $16.74 (market cap $4.73B), while Rocket Companies Inc. Class A Common Stock trades at $10.68 (market cap $29.82B). The key difference: Rocket Companies Inc. Class A Common Stock is far larger — about 6.3× MiniMed Group Inc. Common Stock's market cap, and MiniMed Group Inc. Common Stock is trading nearer its 52-week high, Rocket Companies Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 6 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| MMED | RKT | |
|---|---|---|
Market Cap | $4.73B | $29.82B |
Volume | 67,620,827 | 46,995,062 |
Sector | Health | Financials |
52-Week High | $23.84 | $23.44 |
52-Week Low | $10.80 | $10.53 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.53B | $59.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
